CanSino Biologics Inc

CanSino Biologics Inc. is a biotechnology and biopharmaceuticals company based in the People’s Republic of China. Originally founded in 2009, CanSino Biologics is primarily focused on the clinical stage vaccine market segment. The company has an international focus in terms of distribution and is currently headquartered in Tianjin in the People’s Republic of China. CanSino Biologics Inc. is listed on the Hong Kong Stock Exchange (HKEX) under the 6185.HK ticker. In terms of the performance of the 6185.HK share price, Cansino Biologics Inc. has posted a 52-week high of 285.20 HKD to a 52-week low of 32.90 HKD. It has been traded on the HKEX since it was first listed in July 2018. CanSino Biologics Inc.’s main commercial interests lie in the development and manufacture of vaccines. Some of its most high-profile vaccines include an Ebola virus vaccine, as well as vaccines for the prevention of N. meningitides. In 2020, CanSino Biologics Inc. signed a collaboration agreement with The National Research Council of Canada and Precision NanoSystems Inc. to develop vaccines to combat COVID-19. It was one of the first companies to secure a patent for its COVID-19 vaccine in China. To keep up to date with the latest news, updates, and financial data on the CanSino Biologics Inc. stock, simply add the 6185.HK ticker to your eToro watchlist.